Envisia Therapeutics
Acquired
Extended-release drug delivery for eye disease
- Headquarters
- Research Triangle Park, North Carolina
- Employees
- 11–50
- Founded
- 2013
- Business Model
- B2B
- Website
- envisiatherapeutics.com
- Total Funding
- $41.5M
- Last Round
- $16.5M Extension RoundMar 2016
About
Envisia Therapeutics is a clinical-stage biotechnology company based in Morrisville (Research Triangle Park), North Carolina, focused on developing novel sustained-release drug delivery platforms for ophthalmic diseases. The company's lead product, ENV515, is an extended-release travoprost implant for the treatment of open-angle glaucoma and ocular hypertension. Envisia employs engineered nanoparticle technology for both front-of-eye and back-of-eye drug delivery applications, and debuted with a $25 million Series A financing in November 2013.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account